ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $395,716 | -70.3% | 14,581 | -66.4% | 0.00% | – |
| Q2 2023 | $1,334,146 | +5.2% | 43,401 | +23.3% | 0.00% | – |
| Q1 2023 | $1,268,231 | +41.8% | 35,199 | +55.6% | 0.00% | – |
| Q4 2022 | $894,258 | -42.6% | 22,628 | -41.7% | 0.00% | -100.0% |
| Q3 2022 | $1,558,000 | +5.4% | 38,798 | +10.4% | 0.00% | – |
| Q2 2022 | $1,478,000 | +37.4% | 35,156 | +27.3% | 0.00% | – |
| Q1 2022 | $1,076,000 | +12.2% | 27,609 | +14.7% | 0.00% | – |
| Q4 2021 | $959,000 | -53.4% | 24,066 | -57.7% | 0.00% | – |
| Q3 2021 | $2,056,000 | -52.7% | 56,914 | -46.4% | 0.00% | -100.0% |
| Q2 2021 | $4,350,000 | +178.3% | 106,124 | +196.0% | 0.00% | – |
| Q1 2021 | $1,563,000 | -91.9% | 35,847 | -90.7% | 0.00% | -100.0% |
| Q4 2020 | $19,353,000 | +1464.5% | 386,643 | +1215.2% | 0.01% | – |
| Q3 2020 | $1,237,000 | -93.0% | 29,399 | -92.0% | 0.00% | -100.0% |
| Q2 2020 | $17,786,000 | – | 366,330 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |